Centre National De La Recherche Scientifique

UniversitÉ De Poitiers

Institut National De La Sante Et De La Recherche Medicale

Institut Curie

Université Paris-Saclay

UniversitÉ De Paris

Université De Bretagne Occidentale

Université Victor Segalen—bordeaux 2

Univ Paris Xiii Paris-nord Villetaneuse

Centre Hospitalier Regional Universitaire De Brest

Ecole Normale Superieure

Marc Blondel

Anne Bertolotti

Yvette Mettey

Frederic Becq

Christophe Cullin

Marie-Paule Teulade-Fichou

Jean Michel Vierfond

Nicolas Talarek

Robin Fahraeus

Claire Beauvineau

Cécile Voisset

Chrysoula Daskalogianni

Oksana Reznichenko

Stephane Bach

Anton Granzhan

Alicia Quillevere

Maria José Lista

Rodrigo Prado-Martins

Deborah Triboullard

The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Arand Armay be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Yand Zare independently CH or NR, provided that al least one of Yand Zis NRand at least one of Yand Zis CH,and R, R, R, Xand L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.

Hydrazone derivatives for preventing or treating EBV-related cancers

The invention concerns the use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells, said derivatives corresponding to formula (I), wherein: R&#x2550;H or C1 and the phenyl group comprises two substituents, or a pharmaceutically acceptable salt of said derivatives.

Use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells

The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene, the screening methods, and a family of molecules with anti-prion activity isolated by the inventive screen. The invention is applicable to anti-prion agents for producing medicines in particular for treating neurodegenerative diseases involving protein aggregates.

Screening molecules with anti-prion activity: kits, methods and screened molecules

Growing community of inventors

Saint-Pol de Leon, France

Marc Blondel